Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
3
×
boston top stories
clinical trials
life sciences
national blog main
boston
new york blog main
san francisco blog main
abbvie
agios pharmaceuticals
allergan
alzheimer's disease
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bluebird bio
cancer
cancer drugs
crispr
cynthia collins
david e. shaw
deals
drug discovery
duchenne muscular dystrophy
dyne therapeutics
editas medicine
enasidenib
facioscapulohumeral muscular dystrophy
fda
gene editing
gene therapy
investing
ipo
ivosidenib
joshua brumm
kaleido biosciences
leber congenital amaurosis type 10
materials science
What
experimental
3
×
medicines
3
×
genetic
ipo
abbvie
ago
alliance
biotech
biotechs
company’s
considering
course
data
development
discover
diseases
drug
dyne
early
editas
editing
exits
expected
eyes
gene
growing
handiwork
having
helped
humans
internal
ipos
landscape
long
muscle
pact
partnership
pipeline
pruning
rare
Language
unset
Current search:
experimental
×
medicines
×
" boston blog main "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline